Diego Adrianzen-Herrera, M.D.

Assistant Professor of Medicine, Hematology/Oncology Division, Department of Medicine

Contact Information

Email: dadrianz@uvm.edu

Phone: 802-656-5487

**Office Location:**University of Vermont, Hematology/Oncology Division, 89 Beaumont Avenue, Given Building Suite E214, Burlington, VT 05405

Education

2011 Cayetano Heredia University - Alberto Hurtado School of Medicine, M.D.

Postdoctoral Training

2013 – 2016 Internal Medicine Residency, Icahn School of Medicine at Mount Sinai/Mount Sinai St.

Luke’s - West Hospitals

2016 – 2019 Hematology/Oncology Fellowship, Albert Einstein College of Medicine/Montefiore

Medical Center

Board Certification/Eligibility

2016 American Board of Internal Medicine

2019 American Board of Internal Medicine Subspecialty in Hematology

2019 American Board of Internal Medicine Subspecialty in Medical Oncology

Professional Memberships

American Society for Transplantation and Cellular Therapies (ASTCT)

American Society of Hematology (ASH)

American Society of Clinical Oncology (ASCO)

American College of Physicians (ACP)

American Medical Association (AMA)

Publications

Selected Publications:

Shah UA, Shah N, Qiao B, Acuna-Villaorduna A, Pradhan K, **Adrianzen Herrera D,** Sica A, Shastri A, Mantzaris I, Derman O, Kornblum N, Braunschweig I, Ye H, Verma A, Janakiram M. Epidemiology and survival trend of Adult T-cell leukemia/lymphoma in the United States: An analysis of the NPCR, SEER and NYSCR datasets. Cancer 2019 (Status: Accepted, In Press).

Acuna-Villaorduna A, Gonzalez-Lugo J, Ye H, **Adrianzen Herrera D**, Sica RA, Shah U, Shah N, Kornblum N, Braunschweig I, Derman O, Mantzaris I, Shastri A, Verma A, Zalta B, Janakiram M. High prevalence of pulmonary findings in computed tomographies of HTLV-1 infected patients with and without Adult T-cell leukemia/lymphoma: Implications for staging. Leuk Lymphoma 2019, June 17 [Epub ahead of print].

**Adrianzen Herrera D**, Kornblum N, Derman O, Bachier-Rodriguez L, Sica RA, Shastri A, Janakiram M, Verma A, Braunschweig I, Mantzaris I. Outcomes of autologous hematopoietic stem cell transplantation compared to chemotherapy consolidation alone for non-high risk acute myeloid leukemia in first complete remission in a minority-rich inner-city cohort with limited access to allograft. Clin Lymphoma Myeloma Leuk 2019, Aug;19(8):516-521.

**Adrianzen Herrera D**, Kornblum N, Acuna-Villaorduna A, Sica RA, Shah U, Butler M, Vishnuvardhan N, Shah N, Bachier-Rodriguez L, Derman O, Shastri A, Mantzaris I, Verma A, Braunschweig I, Janakiram M. Barriers to hematopoietic stem cell transplant for human T-Cell lymphotropic virus 1 associated lymphoma-leukemia in the United States: Experience from a large cohort in a major tertiary center. Biol Blood Marrow Transplant 2019, Jun;25(6):e199-e203.

**Adrianzen Herrera D,** Ayyappan S, Jasra S, Kornblum N, Derma O, Shastri A, Mantzaris I, Verma AK, Braunschweig I, Janakiram M. Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant. Leuk Lymphoma 2019, Feb; 60(2):395-401.

Singh AP, **Adrianzen Herrera D,** Zhang Y, Perez-Soler R, Cheng H. Mouse models in squamous cell lung cancer: Impact for drug discovery. Expert Opin Drug Discov 2018,13(4):347-358.

Shah GL, Scordo M, Kosuri S, **Adrianzen Herrera D**, Cho C, Maloy MA, Nieves J, Devlin SM, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O’Reilly RJ, Jakubowski AA, Papadopoulos EB, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Perales MA, Giralt SA, Tamari R. Impact of toxicity on survival for older adult patients after CD34+ selected allogeneic hematopoietic stem cell transplantation. Biol Bone Marrow Transplant 2018;24(1):142-149.

Scordo M, Shah GL, Kosuri S, **Adrianzen Herrera D,** Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Avecilla ST, Meagher RC, Carlow DC, O’Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Tamari R, Perales MA, Giralt SA, Shaffer BC. Effects of late toxicities on outcomes in long-term survivors of ex-vivo CD34+ selected allogeneic hematopoietic cell transplantation. Biol Bone Marrow Transplant 2018;24(1):133-141.

Kosuri S, **Adrianzen Herrera D,** Scordo M, Shah G, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O’Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Tamari R, Giralt S, Perales MA. The impact of toxicities on first year outcomes after Ex-Vivo CD34+ selected allogeneic hematopietic cell transplantation in adults with hematologic malignancies. Biol Bone Marrow Transplant 2017; 23(11):2004-2011.

**Adrianzen Herrera D**, Fleisig S, Gartrell B. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence. Invest New Drugs 2017; 35(5):665-668. PMID: 28466375

Gounder M, Desai V, Kuk D, Agaram N, Arcilla M, Durham B, Keohan ML, Dickson MA, D’Angelo SP, Shukla N, Moskowitz C, Noy A, Maki RG, **Adrianzen Herrera D**, Sanchez A, Krishnan A, Pourmoussa A, Qin LX, Tap WD. Impact of surgery, radiation and systemic therapy on the outcome of patients with dendritic cell and histiocytic sarcomas. Eur J Cancer. 2015;51(16):2413-22. PMID: 26298731

Biographical Information

Dr. Diego Adrianzen Herrera is a hematologist/oncologist at [The University of Vermont Cancer Center](https://www.uvmhealth.org/medcenter/Pages/Departments-and-Programs/Cancer-Center.aspx)and an assistant professor at the Larner College of Medicine at The University of Vermont. He specializes in malignant hematology and hematopoietic stem cell transplant.  His research interests include novel molecular targets and cellular therapies for blood cancers.

Clinical Interests

-Leukemia and Myelodysplastic Syndromes

-Hodgkin’s and Non-Hodgkin’s Lymphoma

-Multiple Myeloma

-Stem cell transplant and cellular therapies

Research Interest

-Mechanisms of clonal hematopoiesis and leukemogenesis

-Molecular targets and cellular therapies for hematologic malignancies

-Health disparities in blood cancer treatment

Education

Fellowship

Albert Einstein College of Medicine/Montefiore Medical Center – Hematology/Oncology

Residency

Icahn School of Medicine at Mount Sinai/Mount Sinai St. Luke’s - West Hospitals – Internal Medicine

Medical School

Cayetano Heredia University – Medical Doctor

Languages

English

Spanish